Arbutus Biopharma (ABUS)
(Delayed Data from NSDQ)
$4.09 USD
+0.10 (2.51%)
Updated Sep 4, 2024 04:00 PM ET
After-Market: $4.10 +0.01 (0.24%) 7:58 PM ET
2-Buy of 5 2
F Value F Growth D Momentum F VGM
Balance Sheet
Fiscal Year End for Arbutus Biopharma Corporation falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 126 | 147 | 155 | 123 | 91 |
Receivables | 2 | 1 | 1 | 1 | 1 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 4 | 3 | 4 | 3 | 2 |
Total Current Assets | 132 | 151 | 161 | 128 | 94 |
Net Property & Equipment | 5 | 5 | 6 | 7 | 9 |
Investments & Advances | 6 | 37 | 36 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 0 | 0 | 0 | 0 | 0 |
Total Assets | 144 | 195 | 204 | 137 | 106 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 10 | 16 | 11 | 9 | 7 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 0 | 0 | 0 | 0 | 0 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 12 | 16 | 0 | 0 | 0 |
Total Current Liabilities | 22 | 33 | 11 | 10 | 8 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 6 | 0 | 0 | 0 |
Other Non-Current Liabilities | 15 | 18 | 22 | 23 | 22 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 38 | 59 | 35 | 35 | 33 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 149 | 137 |
Common Stock (Par) | 1,350 | 1,319 | 1,287 | 986 | 899 |
Capital Surplus | 81 | 72 | 65 | 61 | 55 |
Retained Earnings | -1,277 | -1,204 | -1,134 | -1,046 | -970 |
Other Equity | -48 | -50 | -48 | -48 | -48 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 106 | 137 | 169 | 102 | 73 |
Total Liabilities & Shareholder's Equity | 144 | 195 | 204 | 137 | 106 |
Total Common Equity | 106 | 137 | 169 | -47 | -65 |
Shares Outstanding | 167.70 | 149.90 | 144.90 | 89.60 | 64.70 |
Book Value Per Share | 0.63 | 0.91 | 1.17 | -0.53 | -1.00 |
Fiscal Year End for Arbutus Biopharma Corporation falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 142 | 129 | 126 | 134 | 152 |
Receivables | 2 | 2 | 2 | 2 | 3 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 4 | 4 | 4 | 5 | 4 |
Total Current Assets | 148 | 136 | 132 | 142 | 159 |
Net Property & Equipment | 4 | 4 | 5 | 5 | 5 |
Investments & Advances | 7 | 9 | 6 | 11 | 11 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 0 | 0 | 0 | 0 | 0 |
Total Assets | 160 | 150 | 144 | 159 | 177 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 11 | 8 | 10 | 10 | 9 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 0 | 0 | 0 | 0 | 0 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 11 | 12 | 12 | 12 | 15 |
Total Current Liabilities | 23 | 20 | 22 | 22 | 25 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 14 | 15 | 15 | 16 | |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 38 | 36 | 38 | 39 | 42 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 1,403 | 1,377 | 1,350 | 1,346 | 1,344 |
Capital Surplus | 82 | 80 | 81 | 80 | 77 |
Retained Earnings | -1,314 | -1,295 | -1,277 | -1,257 | -1,237 |
Other Equity | -48 | -48 | -48 | -49 | -49 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 122 | 115 | 106 | 119 | 135 |
Total Liabilities & Shareholder's Equity | 160 | 150 | 144 | 159 | 177 |
Total Common Equity | 122 | 115 | 106 | 119 | 135 |
Shares Outstanding | 188.70 | 180.10 | 167.70 | 167.70 | 166.90 |
Book Value Per Share | 0.65 | 0.64 | 0.63 | 0.71 | 0.81 |